Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Pharmacosmos Holding A/S currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's patent prosecution is spread across different reviewers and technical divisions, reflecting a varied scope for its biotechnology filings. The presence of the pending actions in separate units suggests that the company's intellectual property covers distinct technical classifications within the pharmaceutical field.
LAYLA D BERRY is identified as the busiest examiner for the portfolio, currently handling 1 busiest examiner pending office action. Since there are 2 pending office actions and 2 distinct examiners, the workload is split between different individuals. The involvement of 2 distinct art units suggests that the applications are categorized into two different administrative groups at the patent office, requiring the company to manage interactions across multiple technical units. For practitioners, this means that prosecution strategies must be tailored to the specific expectations of each examiner and the standards of their respective art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 7d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294572 | IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS | BERRY, LAYLA D | 1623 | §102§103§112DP | Non-Final OA | 83d | Pending | Feb 02, 2024 |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 1699 | Other | Non-Final OA | 7d | Pending | Aug 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial